Figure 2

Lack of EP2 suppressed loss of striatal dopamine in MPTP-treated mice. Mice were treated with either a chronic (panel A) or sub-chronic regimen of MPTP (panel B). In the chronic protocol, mice were treated with MPTP (30 mg/kg × 10) and the adjuvant probenecid (250 mg/kg) on a five-week schedule with an interval of 3.5 days between consecutive doses. In the sub-chronic model, mice were treated with MPTP (30 mg/kg*day) or vehicle for five days. Remaining DA in the striatum of mice was measured by HPLC 5 weeks or 5 days post-final treatment in the chronic and subchronic models, respectively. Data are expressed as % control where control mice were the corresponding genotype treated with vehicle. *, **: p < 0.05 and p < 0.01 comparing EP2-/- with WT mice, respectively.